DDInter927 DDInter1909
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.
Valbenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Valbenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Valbenazine may lead to a major life threatening interaction when taken with Enzalutamide
Valbenazine may lead to a major life threatening interaction when taken with Dacomitinib